{"id":"placebo-ii-semaglutide","safety":{"commonSideEffects":[{"rate":"25-40","effect":"Nausea"},{"rate":"10-20","effect":"Vomiting"},{"rate":"20-30","effect":"Diarrhea"},{"rate":"15-25","effect":"Constipation"},{"rate":"10-20","effect":"Abdominal pain"},{"rate":"10-15","effect":"Headache"},{"rate":"5-10","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Semaglutide binds to and activates GLP-1 receptors on pancreatic beta cells, enhancing insulin secretion in response to elevated blood glucose. It also acts on the central nervous system to reduce appetite and increase satiety, while slowing gastric emptying. These combined effects lower blood glucose levels and reduce body weight.","oneSentence":"Semaglutide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 to regulate blood glucose, reduce appetite, and promote weight loss.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:27:30.346Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"},{"name":"Chronic weight management in obese or overweight patients"}]},"trialDetails":[{"nctId":"NCT07466017","phase":"PHASE2","title":"A Study of CS060380 Tablets in Patients With MASH and Obesity","status":"NOT_YET_RECRUITING","sponsor":"Cascade Pharmaceuticals, Inc","startDate":"2026-04-14","conditions":"Metabolic Dysfunction-associated Steatohepatitis (MASH), Obesity","enrollment":120},{"nctId":"NCT07112872","phase":"PHASE2","title":"A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in People With Type 2 Diabetes","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2025-08-19","conditions":"Type 2 Diabetes Mellitus","enrollment":240},{"nctId":"NCT05371496","phase":"PHASE2","title":"Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction","status":"ENROLLING_BY_INVITATION","sponsor":"Mayo Clinic","startDate":"2022-09-06","conditions":"Cardiomyopathy, Heart Failure With Preserved Ejection Fraction (HFpEF), Obesity","enrollment":81},{"nctId":"NCT06015893","phase":"PHASE2","title":"Semaglutide Therapy for Alcohol Reduction (STAR)","status":"RECRUITING","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"2023-10-17","conditions":"Addiction, Alcohol Use Disorder","enrollment":52},{"nctId":"NCT06050577","phase":"PHASE2","title":"The Effect of Oral Semaglutide on Bone Turnover in Patients With T2D: a Randomized Placebo-controlled Clinical Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Odense University Hospital","startDate":"2024-06-07","conditions":"Type 2 Diabetes, Osteopenia","enrollment":64},{"nctId":"NCT06804603","phase":"PHASE2","title":"A Study to Measure the Effects of Using Tradipitant on Nausea and Vomiting After GLP-1R Agonist Use","status":"COMPLETED","sponsor":"Vanda Pharmaceuticals","startDate":"2025-02-25","conditions":"Obesity","enrollment":124},{"nctId":"NCT07163624","phase":"PHASE2","title":"UBT251 Injection Phase II (Type 2 Diabetes Mellitus) Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"The United Bio-Technology (Hengqin) Co., Ltd.","startDate":"2025-03-22","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":211},{"nctId":"NCT05616013","phase":"PHASE2","title":"Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2022-11-16","conditions":"Obesity, Obese, Overweight or Obesity","enrollment":507},{"nctId":"NCT04153929","phase":"PHASE2","title":"A Study to Test Whether Different Doses of BI 456906 Are Effective in Treating Adults With Type 2 Diabetes.","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2020-04-30","conditions":"Diabetes Mellitus, Type 2","enrollment":413},{"nctId":"NCT03552757","phase":"PHASE3","title":"Research Study Investigating How Well Semaglutide Works in People With Type 2 Diabetes Suffering From Overweight or Obesity","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2018-06-04","conditions":"Obesity, Overweight","enrollment":1210}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo II (Semaglutide)","genericName":"Placebo II (Semaglutide)","companyName":"Novo Nordisk A/S","companyId":"novo-nordisk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Semaglutide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 to regulate blood glucose, reduce appetite, and promote weight loss. Used for Type 2 diabetes mellitus, Chronic weight management in obese or overweight patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}